A Grim Toll
The Ebola outbreak in the Democratic Republic of the Congo has become the second-deadliest in the history of Ebola outbreaks in Africa, according to official reports. The Congolese Ministry of Communication and Media reported that the death toll has reached 2,516, with 5,290 infections and a case fatality rate of 47.6%.
The outbreak, which began on May 15 in the DRC and Uganda, has been detected in six Congolese provinces, with the epicenter in Ituri Province. Ugandan authorities announced on July 28 that the Ebola outbreak in their country had ended.
The Virus and the Response
The outbreak is caused by the rare Bundibugyo virus, for which a vaccine is still undergoing clinical trials. The World Health Organization has classified the outbreak as a public health emergency of international concern.
Hospitals and medical isolation centers are currently treating 873 people with symptoms of the disease. The rate of contact tracing among people exposed to Ebola patients stands at 82.9%.
A Perspective on the Figures
Government data from the Ministry of Health, as of Saturday, recorded 5,514 cases and 2,642 deaths, including 317 deaths reported in the previous seven days, making it one of the highest weekly tolls yet. The overall fatality rate is 47.9%, but in hard-to-reach areas like North Kivu province, the rate is considerably higher at 68.6%.
Congolese experts have said the outbreak, which started weeks before it was confirmed, could be three times the known size. Most new cases in Ituri still come from outside monitored contacts.
This is the fastest-growing Ebola outbreak in history, according to United Nations statements cited in news reports. It has recorded seven times more deaths at this stage than the 2014-2016 West Africa Ebola outbreak, which remains the deadliest in history with over 11,000 deaths.
The disease has killed more than 15,000 people in Africa over the past 50 years, according to historical data referenced by experts.
Challenges and Hope
The outbreak is unfolding under challenging conditions, including rebel threats, intense population movements, work stoppages by unpaid responders, community anger, bad roads, and misinformation. These factors have hindered the response and contributed to the rapid spread.
A key challenge has been the lack of approved vaccines or treatments for the Bundibugyo virus. However, on Friday, the DRC received more than 16,000 doses of the Ervebo vaccine, which was effective in past Ebola outbreaks caused by a different, more common type. The WHO says it will also be used in clinical trials for a Bundibugyo virus vaccine.
WHO officials note that it is not yet known whether Ervebo can protect against the Bundibugyo virus, although early laboratory and animal data suggest it may offer some protection. Officials have not specified when the vaccine will be rolled out to frontline workers, but in Ituri, locals expressed optimism. One resident, Héritier Ramazani, said, "I am very pleased that these vaccines have finally arrived. We are fed up with recording new cases of Ebola every day."